To test the hypothesis that targeting sMIC can enhance the therapeutic potential of IL-15 superagonist ALT-803 in a pre-clinical model, we developed multiple transplantable syngeneic tumor models by: 1) overexpressing human soluble MICB in transplantable mouse tumor cell lines, and 2) inoculating tumor lines secreting sMICB into the MICB transgenic mouse. This evidence concerns the gene MICB and neoplasm.